{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:36:34Z","timestamp":1790674594066,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Huntington\u2019s disease (HD) is a progressive inherited neurological disease characterized by the degeneration of basal ganglia and the accumulation of mutant huntingtin (mHtt) aggregates in specific brain areas. Currently, there is no treatment for halting the progression of HD. Cerebral dopamine neurotrophic factor (CDNF) is a novel endoplasmic reticulum located protein with neurotrophic factor properties that protects and restores dopamine neurons in rodent and non-human primate models of Parkinson\u2019s disease. Our recent study showed that CDNF improves motor coordination and protects NeuN positive cells in a Quinolinic acid toxin rat model of HD. Here we have investigated the effect of chronic intrastriatal CDNF administration on behavior and mHtt aggregates in the N171-82Q mouse model of HD. Data showed that CDNF did not significantly decrease the number of mHtt aggregates in most brain regions studied. Notably, CDNF significantly delayed the onset of symptoms and improved motor coordination in N171-82Q mice. Furthermore, CDNF increased <jats:italic>BDNF<\/jats:italic> mRNA level in hippocampus in vivo in the N171-82Q model and BDNF protein level in cultured striatal neurons. Collectively our results indicate that CDNF\u00a0might be a potential drug candidate for the treatment of HD.<\/jats:p>","DOI":"10.1038\/s41598-023-28798-4","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:04:35Z","timestamp":1676894675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington\u2019s disease"],"prefix":"10.1038","volume":"13","author":[{"given":"P.","family":"Stepanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Cavonius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Korpikoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sirjala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H.","family":"Voutilainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"28798_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.3155875","volume":"227","author":"GA Graveland","year":"1985","unstructured":"Graveland, G. A., Williams, R. S. & DiFiglia, M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington\u2019s disease. Science 227, 770\u2013773. https:\/\/doi.org\/10.1126\/science.3155875 (1985).","journal-title":"Science"},{"key":"28798_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1212\/wnl.23.6.561","volume":"23","author":"RK Byers","year":"1973","unstructured":"Byers, R. K., Gilles, F. H. & Fung, C. Huntington\u2019s disease in children. Neuropathologic study of four cases. Neurology 23, 561\u2013569. https:\/\/doi.org\/10.1212\/wnl.23.6.561 (1973).","journal-title":"Neurology"},{"key":"28798_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-e","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983. https:\/\/doi.org\/10.1016\/0092-8674(93)90585-e (1993).","journal-title":"Cell"},{"key":"28798_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/cne.10295","volume":"449","author":"CA Meade","year":"2002","unstructured":"Meade, C. A. et al. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6\/2 transgenic mice. J. Comput. Neurol. 449, 241\u2013269. https:\/\/doi.org\/10.1002\/cne.10295 (2002).","journal-title":"J. Comput. Neurol."},{"key":"28798_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","volume":"8","author":"G Schilling","year":"1999","unstructured":"Schilling, G. et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397\u2013407. https:\/\/doi.org\/10.1093\/hmg\/8.3.397 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"28798_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cne.20680","volume":"490","author":"EC Stack","year":"2005","unstructured":"Stack, E. C. et al. Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington\u2019s disease transgenic mice. J. Comput. Neurol. 490, 354\u2013370. https:\/\/doi.org\/10.1002\/cne.20680 (2005).","journal-title":"J. Comput. Neurol."},{"key":"28798_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537\u2013548. https:\/\/doi.org\/10.1016\/s0092-8674(00)80513-9 (1997).","journal-title":"Cell"},{"key":"28798_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493\u2013506. https:\/\/doi.org\/10.1016\/s0092-8674(00)81369-0 (1996).","journal-title":"Cell"},{"key":"28798_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","volume":"1792","author":"RJ Ferrante","year":"2009","unstructured":"Ferrante, R. J. Mouse models of Huntington\u2019s disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta 1792, 506\u2013520. https:\/\/doi.org\/10.1016\/j.bbadis.2009.04.001 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"28798_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","volume":"69","author":"ZR Crook","year":"2011","unstructured":"Crook, Z. R. & Housman, D. Huntington\u2019s disease: Can mice lead the way to treatment?. Neuron 69, 423\u2013435. https:\/\/doi.org\/10.1016\/j.neuron.2010.12.035 (2011).","journal-title":"Neuron"},{"key":"28798_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1006\/nbdi.2001.0385","volume":"8","author":"G Schilling","year":"2001","unstructured":"Schilling, G. et al. Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol. Dis. 8, 405\u2013418. https:\/\/doi.org\/10.1006\/nbdi.2001.0385 (2001).","journal-title":"Neurobiol. Dis."},{"key":"28798_CR12","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","volume":"17","author":"CE Wang","year":"2008","unstructured":"Wang, C. E. et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington\u2019s disease. Hum. Mol. Genet. 17, 2738\u20132751. https:\/\/doi.org\/10.1093\/hmg\/ddn175 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"28798_CR13","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1073\/pnas.0508875103","volume":"103","author":"JL McBride","year":"2006","unstructured":"McBride, J. L. et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington\u2019s disease. Proc. Natl. Acad. Sci. U. S. A. 103, 9345\u20139350. https:\/\/doi.org\/10.1073\/pnas.0508875103 (2006).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"28798_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.nbd.2008.12.005","volume":"34","author":"S Ramaswamy","year":"2009","unstructured":"Ramaswamy, S. et al. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington\u2019s disease. Neurobiol. Dis. 34, 40\u201350. https:\/\/doi.org\/10.1016\/j.nbd.2008.12.005 (2009).","journal-title":"Neurobiol. Dis."},{"key":"28798_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","volume":"8","author":"OA Andreassen","year":"2001","unstructured":"Andreassen, O. A. et al. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease. Neurobiol. Dis. 8, 479\u2013491. https:\/\/doi.org\/10.1006\/nbdi.2001.0406 (2001).","journal-title":"Neurobiol. Dis."},{"key":"28798_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0166-2236(00)01721-5","volume":"24","author":"E Cattaneo","year":"2001","unstructured":"Cattaneo, E. et al. Loss of normal huntingtin function: New developments in Huntington\u2019s disease research. Trends Neurosci. 24, 182\u2013188. https:\/\/doi.org\/10.1016\/s0166-2236(00)01721-5 (2001).","journal-title":"Trends Neurosci."},{"key":"28798_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0006-8993(02)03222-5","volume":"952","author":"LL Pedre","year":"2002","unstructured":"Pedre, L. L. et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res. 952, 122\u2013127. https:\/\/doi.org\/10.1016\/S0006-8993(02)03222-5 (2002).","journal-title":"Brain Res."},{"key":"28798_CR18","doi-asserted-by":"publisher","first-page":"e22966","DOI":"10.1371\/journal.pone.0022966","volume":"6","author":"C Zuccato","year":"2011","unstructured":"Zuccato, C. et al. Brain-derived neurotrophic factor in patients with Huntington\u2019s disease. PLoS ONE 6, e22966. https:\/\/doi.org\/10.1371\/journal.pone.0022966 (2011).","journal-title":"PLoS ONE"},{"key":"28798_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1750-3639.2006.00036.x","volume":"16","author":"A Blesch","year":"2006","unstructured":"Blesch, A. Neurotrophic factors in neurodegeneration. Brain Pathol. 16, 295\u2013303. https:\/\/doi.org\/10.1111\/j.1750-3639.2006.00036.x (2006).","journal-title":"Brain Pathol."},{"key":"28798_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U. & Patel, N. K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Therapeut. 138, 155\u2013175. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.01.004 (2013).","journal-title":"Pharmacol. Therapeut."},{"key":"28798_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/0963689719840290","volume":"28","author":"HJ Huttunen","year":"2019","unstructured":"Huttunen, H. J. & Saarma, M. CDNF protein therapy in Parkinson\u2019s disease. Cell Transpl. 28, 349\u2013366. https:\/\/doi.org\/10.1177\/0963689719840290 (2019).","journal-title":"Cell Transpl."},{"key":"28798_CR22","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0117-16.2017","author":"MH Voutilainen","year":"2017","unstructured":"Voutilainen, M. H. et al. Evidence for an additive neurorestorative effect of simultaneously administered CDNF and GDNF in hemiparkinsonian rats: Implications for different mechanism of action. eNeuro https:\/\/doi.org\/10.1523\/ENEURO.0117-16.2017 (2017).","journal-title":"eNeuro"},{"key":"28798_CR23","doi-asserted-by":"publisher","first-page":"19045","DOI":"10.1038\/s41598-020-75439-1","volume":"10","author":"P Stepanova","year":"2020","unstructured":"Stepanova, P., Srinivasan, V., Lindholm, D. & Voutilainen, M. H. Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington\u2019s disease. Sci. Rep. 10, 19045. https:\/\/doi.org\/10.1038\/s41598-020-75439-1 (2020).","journal-title":"Sci. Rep."},{"key":"28798_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.05.078618","author":"F De Lorenzo","year":"2020","unstructured":"De Lorenzo, F. et al. CDNF rescues motor neurons in three animal models of ALS by targeting ER stress. bioRxiv https:\/\/doi.org\/10.1101\/2020.05.05.078618 (2020).","journal-title":"bioRxiv"},{"key":"28798_CR25","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.yexcr.2008.05.001","volume":"314","author":"A Apostolou","year":"2008","unstructured":"Apostolou, A., Shen, Y., Liang, Y., Luo, J. & Fang, S. Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp. Cell Res. 314, 2454\u20132467. https:\/\/doi.org\/10.1016\/j.yexcr.2008.05.001 (2008).","journal-title":"Exp. Cell Res."},{"key":"28798_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00059-017-4564-3","volume":"43","author":"H Liu","year":"2018","unstructured":"Liu, H. et al. Cerebral dopamine neurotrophic factor protects H9c2 cardiomyocytes from apoptosis. Herz 43, 346\u2013351. https:\/\/doi.org\/10.1007\/s00059-017-4564-3 (2018).","journal-title":"Herz"},{"key":"28798_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature05957","volume":"448","author":"P Lindholm","year":"2007","unstructured":"Lindholm, P. et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448, 73\u201377. https:\/\/doi.org\/10.1038\/nature05957 (2007).","journal-title":"Nature"},{"key":"28798_CR28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3389\/fendo.2019.00765","volume":"10","author":"T Danilova","year":"2019","unstructured":"Danilova, T. et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is highly expressed in mouse tissues with metabolic function. Front. Endocrinol. 10, 765. https:\/\/doi.org\/10.3389\/fendo.2019.00765 (2019).","journal-title":"Front. Endocrinol."},{"key":"28798_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nbd.2016.07.009","volume":"97","author":"M Lindahl","year":"2017","unstructured":"Lindahl, M., Saarma, M. & Lindholm, P. Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential. Neurobiol. Dis. 97, 90\u2013102. https:\/\/doi.org\/10.1016\/j.nbd.2016.07.009 (2017).","journal-title":"Neurobiol. Dis."},{"key":"28798_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/dneu.20760","volume":"70","author":"P Lindholm","year":"2010","unstructured":"Lindholm, P. & Saarma, M. Novel CDNF\/MANF family of neurotrophic factors. Dev. Neurobiol. 70, 360\u2013371. https:\/\/doi.org\/10.1002\/dneu.20760 (2010).","journal-title":"Dev. Neurobiol."},{"key":"28798_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/protein\/gzn080","volume":"22","author":"V Parkash","year":"2009","unstructured":"Parkash, V. et al. The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng. Des. Sel. 22, 233\u2013241. https:\/\/doi.org\/10.1093\/protein\/gzn080 (2009).","journal-title":"Protein Eng. Des. Sel."},{"key":"28798_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.plasmid.2014.09.001","volume":"76","author":"A Fernandez","year":"2014","unstructured":"Fernandez, A., Guzman, S., Cruz, Y. & Zamorano, P. Construction of bicistronic lentiviral vectors for tracking the expression of CDNF in transduced cells. Plasmid 76, 15\u201323. https:\/\/doi.org\/10.1016\/j.plasmid.2014.09.001 (2014).","journal-title":"Plasmid"},{"key":"28798_CR33","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.bbamcr.2018.08.012","volume":"1865","author":"D Arancibia","year":"2018","unstructured":"Arancibia, D., Zamorano, P. & Andres, M. E. CDNF induces the adaptive unfolded protein response and attenuates endoplasmic reticulum stress-induced cell death. BBA-Mol. Cell. Res. 1865, 1579\u20131589. https:\/\/doi.org\/10.1016\/j.bbamcr.2018.08.012 (2018).","journal-title":"BBA-Mol. Cell. Res."},{"key":"28798_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169489","author":"A Eesmaa","year":"2022","unstructured":"Eesmaa, A. et al. CDNF interacts with ER chaperones and requires UPR sensors to promote neuronal survival. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23169489 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"28798_CR35","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41380-021-01394-6","volume":"27","author":"P Lindholm","year":"2022","unstructured":"Lindholm, P. & Saarma, M. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol. Psychiatry 27, 1310\u20131321. https:\/\/doi.org\/10.1038\/s41380-021-01394-6 (2022).","journal-title":"Mol. Psychiatry"},{"key":"28798_CR36","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0128-16.2017","author":"K Matlik","year":"2017","unstructured":"Matlik, K. et al. Intrastriatally infused exogenous CDNF Is endocytosed and retrogradely transported to substantia nigra. eNeuro https:\/\/doi.org\/10.1523\/ENEURO.0128-16.2017 (2017).","journal-title":"eNeuro"},{"key":"28798_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.expneurol.2010.12.013","volume":"228","author":"MH Voutilainen","year":"2011","unstructured":"Voutilainen, M. H. et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson\u2019s disease. Exp. Neurol. 228, 99\u2013108. https:\/\/doi.org\/10.1016\/j.expneurol.2010.12.013 (2011).","journal-title":"Exp. Neurol."},{"key":"28798_CR38","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3727\/096368911X600948","volume":"21","author":"M Airavaara","year":"2012","unstructured":"Airavaara, M. et al. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transpl. 21, 1213\u20131223. https:\/\/doi.org\/10.3727\/096368911X600948 (2012).","journal-title":"Cell Transpl."},{"key":"28798_CR39","doi-asserted-by":"publisher","first-page":"e0149776","DOI":"10.1371\/journal.pone.0149776","volume":"11","author":"E Garea-Rodriguez","year":"2016","unstructured":"Garea-Rodriguez, E. et al. Comparative analysis of the effects of neurotrophic factors CDNF and GDNF in a nonhuman primate model of Parkinson\u2019s disease. PLoS ONE 11, e0149776. https:\/\/doi.org\/10.1371\/journal.pone.0149776 (2016).","journal-title":"PLoS ONE"},{"key":"28798_CR40","doi-asserted-by":"publisher","DOI":"10.3791\/1787","author":"SJ Guyenet","year":"2010","unstructured":"Guyenet, S. J. et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J. Vis. Exp. https:\/\/doi.org\/10.3791\/1787 (2010).","journal-title":"J. Vis. Exp."},{"key":"28798_CR41","doi-asserted-by":"publisher","first-page":"32845","DOI":"10.1074\/jbc.M114.612424","volume":"289","author":"K Kannike","year":"2014","unstructured":"Kannike, K., Sepp, M., Zuccato, C., Cattaneo, E. & Timmusk, T. Forkhead transcription factor FOXO3a levels are increased in Huntington disease because of overactivated positive autofeedback loop. J. Biol. Chem. 289, 32845\u201332857. https:\/\/doi.org\/10.1074\/jbc.M114.612424 (2014).","journal-title":"J. Biol. Chem."},{"key":"28798_CR42","doi-asserted-by":"publisher","first-page":"100790","DOI":"10.1016\/j.isci.2019.100790","volume":"23","author":"V Srinivasan","year":"2020","unstructured":"Srinivasan, V. et al. Dynamic interaction of USP14 with the chaperone HSC70 mediates crosstalk between the proteasome, ER signaling, and autophagy. iScience 23, 100790. https:\/\/doi.org\/10.1016\/j.isci.2019.100790 (2020).","journal-title":"iScience"},{"key":"28798_CR43","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1093\/hmg\/ddu317","volume":"23","author":"A Hyrskyluoto","year":"2014","unstructured":"Hyrskyluoto, A. et al. Ubiquitin-specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: Involvement of the proteasome and ER stress-activated kinase IRE1alpha. Hum. Mol. Genet. 23, 5928\u20135939. https:\/\/doi.org\/10.1093\/hmg\/ddu317 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"28798_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/brb3.117","volume":"3","author":"S Back","year":"2013","unstructured":"Back, S. et al. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson\u2019s disease. Brain Behav. 3, 75\u201388. https:\/\/doi.org\/10.1002\/brb3.117 (2013).","journal-title":"Brain Behav."},{"key":"28798_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12035-014-9000-6","volume":"53","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. Transplantation of cerebral dopamine neurotrophic factor transducted BMSCs in contusion spinal cord injury of rats: Promotion of nerve regeneration by alleviating neuroinflammation. Mol. Neurobiol. 53, 187\u2013199. https:\/\/doi.org\/10.1007\/s12035-014-9000-6 (2016).","journal-title":"Mol. Neurobiol."},{"key":"28798_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12974-014-0209-0","volume":"11","author":"R Nadella","year":"2014","unstructured":"Nadella, R. et al. Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. J. Neuroinflammation 11, 209. https:\/\/doi.org\/10.1186\/s12974-014-0209-0 (2014).","journal-title":"J. Neuroinflammation"},{"key":"28798_CR47","unstructured":"Herantis Pharma. Available online at: https:\/\/herantis.com\/wp-content\/uploads\/2020\/09\/200915-CDNF-Webinar_FINAL.pdf (accessed Nov 3, 2020) (2020)."},{"key":"28798_CR48","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1093\/hmg\/dds379","volume":"21","author":"H Jia","year":"2012","unstructured":"Jia, H., Kast, R. J., Steffan, J. S. & Thomas, E. A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington\u2019s disease mice: Implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet. 21, 5280\u20135293. https:\/\/doi.org\/10.1093\/hmg\/dds379 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"28798_CR49","doi-asserted-by":"publisher","first-page":"16027","DOI":"10.1074\/jbc.M710606200","volume":"283","author":"AL Orr","year":"2008","unstructured":"Orr, A. L. et al. Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice. J. Biol. Chem. 283, 16027\u201316036. https:\/\/doi.org\/10.1074\/jbc.M710606200 (2008).","journal-title":"J. Biol. Chem."},{"key":"28798_CR50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.nbd.2015.05.011","volume":"82","author":"S Swarnkar","year":"2015","unstructured":"Swarnkar, S. et al. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington\u2019s disease. Neurobiol. Dis. 82, 66\u201377. https:\/\/doi.org\/10.1016\/j.nbd.2015.05.011 (2015).","journal-title":"Neurobiol. Dis."},{"key":"28798_CR51","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1111\/j.1742-4658.2008.06561.x","volume":"275","author":"R Truant","year":"2008","unstructured":"Truant, R., Atwal, R. S., Desmond, C., Munsie, L. & Tran, T. Huntington\u2019s disease: Revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 275, 4252\u20134262. https:\/\/doi.org\/10.1111\/j.1742-4658.2008.06561.x (2008).","journal-title":"FEBS J."},{"key":"28798_CR52","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/ncomms3753","volume":"4","author":"J Leitman","year":"2013","unstructured":"Leitman, J., Ulrich Hartl, F. & Lederkremer, G. Z. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nat. Commun. 4, 2753. https:\/\/doi.org\/10.1038\/ncomms3753 (2013).","journal-title":"Nat. Commun."},{"key":"28798_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nature02998","volume":"431","author":"M Arrasate","year":"2004","unstructured":"Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805\u2013810. https:\/\/doi.org\/10.1038\/nature02998 (2004).","journal-title":"Nature"},{"key":"28798_CR54","doi-asserted-by":"publisher","first-page":"10855","DOI":"10.1074\/jbc.M804813200","volume":"284","author":"T Ratovitski","year":"2009","unstructured":"Ratovitski, T. et al. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J. Biol. Chem. 284, 10855\u201310867. https:\/\/doi.org\/10.1074\/jbc.M804813200 (2009).","journal-title":"J. Biol. Chem."},{"key":"28798_CR55","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","volume":"19","author":"CA Gutekunst","year":"1999","unstructured":"Gutekunst, C. A. et al. Nuclear and neuropil aggregates in Huntington\u2019s disease: Relationship to neuropathology. J. Neurosci. 19, 2522\u20132534 (1999).","journal-title":"J. Neurosci."},{"key":"28798_CR56","doi-asserted-by":"publisher","first-page":"e0155834","DOI":"10.1371\/journal.pone.0155834","volume":"11","author":"Z Bayram-Weston","year":"2016","unstructured":"Bayram-Weston, Z., Jones, L., Dunnett, S. B. & Brooks, S. P. Comparison of mHTT antibodies in Huntington\u2019s disease mouse models reveal specific binding profiles and steady-state ubiquitin levels with disease development. PLoS ONE 11, e0155834. https:\/\/doi.org\/10.1371\/journal.pone.0155834 (2016).","journal-title":"PLoS ONE"},{"key":"28798_CR57","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1101\/gad.1673408","volume":"22","author":"ML Duennwald","year":"2008","unstructured":"Duennwald, M. L. & Lindquist, S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev. 22, 3308\u20133319. https:\/\/doi.org\/10.1101\/gad.1673408 (2008).","journal-title":"Genes Dev."},{"key":"28798_CR58","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/hmg\/ddy061","volume":"27","author":"X Zhou","year":"2018","unstructured":"Zhou, X. et al. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington\u2019s disease. Hum Mol Genet 27, 1545\u20131555. https:\/\/doi.org\/10.1093\/hmg\/ddy061 (2018).","journal-title":"Hum Mol Genet"},{"key":"28798_CR59","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.yexcr.2007.12.025","volume":"314","author":"S Reijonen","year":"2008","unstructured":"Reijonen, S., Putkonen, N., Norremolle, A., Lindholm, D. & Korhonen, L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp. Cell Res. 314, 950\u2013960. https:\/\/doi.org\/10.1016\/j.yexcr.2007.12.025 (2008).","journal-title":"Exp. Cell Res."},{"key":"28798_CR60","doi-asserted-by":"publisher","first-page":"18167","DOI":"10.1074\/jbc.M109.018325","volume":"284","author":"A Carnemolla","year":"2009","unstructured":"Carnemolla, A. et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J. Biol. Chem. 284, 18167\u201318173. https:\/\/doi.org\/10.1074\/jbc.M109.018325 (2009).","journal-title":"J. Biol. Chem."},{"key":"28798_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293, 493\u2013498. https:\/\/doi.org\/10.1126\/science.1059581 (2001).","journal-title":"Science"},{"key":"28798_CR62","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/39885","volume":"389","author":"CA Altar","year":"1997","unstructured":"Altar, C. A. et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389, 856\u2013860. https:\/\/doi.org\/10.1038\/39885 (1997).","journal-title":"Nature"},{"key":"28798_CR63","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","volume":"24","author":"A Miguez","year":"2015","unstructured":"Miguez, A. et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington\u2019s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum. Mol. Genet. 24, 4958\u20134970. https:\/\/doi.org\/10.1093\/hmg\/ddv218 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"28798_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2015.05.002","volume":"291","author":"S Kemppainen","year":"2015","unstructured":"Kemppainen, S. et al. Cerebral dopamine neurotrophic factor improves long-term memory in APP\/PS1 transgenic mice modeling Alzheimer\u2019s disease as well as in wild-type mice. Behav. Brain Res. 291, 1\u201311. https:\/\/doi.org\/10.1016\/j.bbr.2015.05.002 (2015).","journal-title":"Behav. Brain Res."},{"key":"28798_CR65","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.celrep.2016.01.028","volume":"14","author":"G Martinez","year":"2016","unstructured":"Martinez, G. et al. Regulation of memory formation by the transcription factor XBP1. Cell Rep. 14, 1382\u20131394. https:\/\/doi.org\/10.1016\/j.celrep.2016.01.028 (2016).","journal-title":"Cell Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28798-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:05:23Z","timestamp":1676894723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28798-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28798"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28798-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"11 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Merja H Voutilainen is an inventor of the CDNF-patent, which is owned by Herantis Pharma Plc. Other authors do not have competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2953"}}